Novonesis: The enzyme champion that no one can copy

5-year stock timeline

Key Points

From recommendation (January 4, 2026)

• Market leader with almost 50% share in the specialty enzyme segment - decades of research and thousands of patented enzymes create an almost uncopyable competitive advantage
• Merger with Chr. Hansen successfully completed, sales growth forecast for 2025 raised to 7-8% organically
• Enzymes de facto indispensable in food, detergents and biofuels - chemical alternatives more expensive, more harmful to the environment and problematic from a regulatory perspective
• P/E ratio 15.5 with structural growth due to decarbonization pressure and expansion in emerging markets
• New Quara LowP product line addresses growing market for sustainable aviation fuel

Investment Thesis

From recommendation (January 4, 2026)

Novonesis unites according to the Chr. Hansen merger offers a unique combination of technological dominance, operational scaling and structural tailwind. The company controls a market in which enzymes are not only efficient, but increasingly without alternative - be it in food processing, biofuels or low-temperature detergents. Entering this market requires decades of research, extensive master collections, regulatory approvals and deep customer relationships - hurdles that remain virtually insurmountable. At the same time, global decarbonization pressure is structurally driving demand for biological process solutions, while the merger is showing initial synergies and strategically expanding the portfolio. With a P/E ratio of 15.5, an increased growth forecast and expansion potential in emerging markets, the share offers solid fundamental data with limited disruption risk until at least 2035.

Key risks and downside factors

Novozymes operates in a concentrated global market for enzymes and microbial ingredients where it faces formidable competition from large specialty-chemical and ingredient groups. DuPont, BASF, DSM‑Firmenich and Chr. Hansen all compete directly, which keeps pressure on pricing, market share and R&D spending. The business faces meaningful structural constraints: regulatory approval cycles can be lengthy, supply chains remain exposed to disruption, and the market demands constant product innovation—all of which weigh on growth prospects and margin sustainability.

• Large chemical and ingredient groups—DuPont, BASF, DSM-Firmenich, Chr. Hansen—are intensifying their competitive presence, which could pressure both pricing and market share.
• Failure to maintain R&D productivity or adequately protect proprietary enzyme technologies risks eroding the company's competitive differentiation and pressuring long-term margins [4][2].
• Specialty enzyme applications in food, agriculture, and biofuels face regulatory scrutiny and slower-than-expected commercial adoption, which can push out revenue recognition and delay meaningful market penetration.
• Supply-chain disruptions, raw-material price swings, and foreign-exchange exposure can all work against margins for companies operating globally.

Competitive landscape

Novozymes (now part of Novonesis following the 2024 merger) holds a commanding position in industrial enzymes and microbial solutions across household care, food & beverages, bioenergy, agriculture and feed. The competitive landscape is dense—IFF, BASF, and DSM-Firmenich all operate in overlapping spaces, which keeps pressure on both pricing and the need to stay ahead on innovation. The business carries inherent sector cyclicality, and there's the usual execution risk that comes with integration work, alongside the persistent weight of supply-chain dynamics on margins.

Catalysts

From recommendation (January 4, 2026)

• Further synergy effects from Chr. Hansen merger could noticeably improve margins from 2026
• Regulatory tightening for decarbonization structurally driving demand for enzyme-based solutions
• Breakthroughs in sustainable aviation fuels with Quara LowP could open up new growth segment
• Successful expansion in emerging markets with rising demand for food and detergent enzymes

Analysis

From recommendation (January 4, 2026)

Performance Figures of Novonesis (Novozymes) A/S

in DKK

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

From recommendation (January 4, 2026)

Key Metrics

From recommendation (January 4, 2026)

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.